MX2007012537A - Combinaciones, metodos y composiciones para tratamiento del cancer. - Google Patents
Combinaciones, metodos y composiciones para tratamiento del cancer.Info
- Publication number
- MX2007012537A MX2007012537A MX2007012537A MX2007012537A MX2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A MX 2007012537 A MX2007012537 A MX 2007012537A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- combinations
- treating cancer
- bcr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67074405P | 2005-04-13 | 2005-04-13 | |
US74843305P | 2005-12-08 | 2005-12-08 | |
US11/402,502 US20060235006A1 (en) | 2005-04-13 | 2006-04-12 | Combinations, methods and compositions for treating cancer |
PCT/US2006/013773 WO2006113304A2 (en) | 2005-04-13 | 2006-04-13 | Combinations, methods and compositions for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007012537A true MX2007012537A (es) | 2007-12-10 |
Family
ID=37109315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007012537A MX2007012537A (es) | 2005-04-13 | 2006-04-13 | Combinaciones, metodos y composiciones para tratamiento del cancer. |
Country Status (12)
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA01010292A (es) | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
DE602006021312D1 (de) * | 2005-06-09 | 2011-05-26 | Bristol Myers Squibb Co | Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit-protein |
AR057854A1 (es) | 2005-11-04 | 2007-12-19 | Wyeth Corp | Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida |
US20090099197A1 (en) * | 2005-11-15 | 2009-04-16 | Bristol-Myers Squibb Company | Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof |
KR20140020367A (ko) * | 2006-04-05 | 2014-02-18 | 노파르티스 아게 | 암을 치료하기 위한 bcr-abl/c-kit/pdgf-r tk 억제제를 포함하는 조합물 |
EP2010182A2 (en) * | 2006-04-07 | 2009-01-07 | Novartis AG | Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia |
WO2008064004A2 (en) * | 2006-11-16 | 2008-05-29 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
WO2008089135A2 (en) * | 2007-01-12 | 2008-07-24 | University Of South Florida | Identification of biomarkers predictive of dasatinib effects in cancer cells |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009076373A1 (en) * | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
JP5681108B2 (ja) * | 2008-08-04 | 2015-03-04 | ワイス・エルエルシー | 4−アニリノ−3−シアノキノリンとカペシタビンの抗新生物薬の組合せ |
US20100233172A1 (en) * | 2008-12-16 | 2010-09-16 | Bristol-Myers Squibb Company | Methods of inhibiting quiescent tumor proliferation |
HUE033312T2 (en) * | 2009-07-20 | 2017-11-28 | Bristol Myers Squibb Co | Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases |
JP2013505968A (ja) * | 2009-10-01 | 2013-02-21 | シーエスエル、リミテッド | フィラデルフィア染色体陽性白血病の治療方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
MXPA01010292A (es) * | 1999-04-15 | 2002-10-23 | Squibb Bristol Myers Co | Inhibidores ciclicos de la proteina tirosina cinasa. |
TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
EP2253319A1 (en) * | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent. |
EP1534862A4 (en) * | 2002-08-07 | 2007-10-10 | Exelixis Inc | RABGGT MODULATORS AND METHODS OF USE THEREOF |
US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
AR047530A1 (es) * | 2004-02-04 | 2006-01-25 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida |
US7491725B2 (en) * | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
-
2006
- 2006-04-12 US US11/402,502 patent/US20060235006A1/en not_active Abandoned
- 2006-04-13 AU AU2006236812A patent/AU2006236812A1/en not_active Abandoned
- 2006-04-13 EP EP06749971A patent/EP1868435A4/en not_active Withdrawn
- 2006-04-13 KR KR1020077023422A patent/KR20080004495A/ko not_active Application Discontinuation
- 2006-04-13 CA CA002604581A patent/CA2604581A1/en not_active Abandoned
- 2006-04-13 TW TW095113103A patent/TW200722091A/zh unknown
- 2006-04-13 WO PCT/US2006/013773 patent/WO2006113304A2/en active Application Filing
- 2006-04-13 MX MX2007012537A patent/MX2007012537A/es not_active Application Discontinuation
- 2006-04-13 BR BRPI0608176-2A patent/BRPI0608176A2/pt not_active IP Right Cessation
- 2006-04-13 EA EA200702238A patent/EA200702238A1/ru unknown
- 2006-04-13 JP JP2008506668A patent/JP2008536853A/ja not_active Withdrawn
-
2007
- 2007-10-09 NO NO20075087A patent/NO20075087L/no not_active Application Discontinuation
-
2008
- 2008-10-23 US US12/256,771 patent/US20090054415A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20075087L (no) | 2008-01-09 |
JP2008536853A (ja) | 2008-09-11 |
EP1868435A4 (en) | 2009-04-01 |
US20060235006A1 (en) | 2006-10-19 |
EA200702238A1 (ru) | 2008-04-28 |
CA2604581A1 (en) | 2006-10-26 |
BRPI0608176A2 (pt) | 2009-11-17 |
AU2006236812A1 (en) | 2006-10-26 |
US20090054415A1 (en) | 2009-02-26 |
KR20080004495A (ko) | 2008-01-09 |
TW200722091A (en) | 2007-06-16 |
EP1868435A2 (en) | 2007-12-26 |
WO2006113304A3 (en) | 2007-08-02 |
WO2006113304A2 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007012537A (es) | Combinaciones, metodos y composiciones para tratamiento del cancer. | |
GEP20104927B (en) | Formulations of a src/abl inhibitor | |
IL194744A (en) | Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases | |
PE20061394A1 (es) | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas | |
AR112118A2 (es) | Inhibidores de pi-3 quinasa | |
AR104566A2 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
EA200800727A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
IL205697A0 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof | |
SG162790A1 (en) | Aspartyl protease inhibitors | |
ATE481093T1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
EA200702568A1 (ru) | Гетеробициклические ингибиторы металлопротеазы и их применение | |
TN2009000225A1 (en) | Compounds and compositions as protein kinase kinase inhibitors | |
EA201100688A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
WO2007125310A3 (en) | Pharmaceutical combinations of pk inhibitors and other active agents | |
NO20092412L (no) | Hydantoinderivater anvendes som MMP-inhibitorer | |
UA96126C2 (ru) | Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
UA92914C2 (ru) | Гетероциклические соединения как положительные аллостерические модуляторы метаботропных глутаматных рецепторов | |
NO20084923L (no) | N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer | |
ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
EP1951709A4 (en) | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
WO2007068728A3 (en) | N-substituted pyrrolopyridinones active as kinase inhibitors | |
MX2009012525A (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa. | |
PE20091617A1 (es) | Tiazolil-dihidro-indazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |